全文获取类型
收费全文 | 4037篇 |
免费 | 313篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 139篇 |
妇产科学 | 131篇 |
基础医学 | 674篇 |
口腔科学 | 268篇 |
临床医学 | 383篇 |
内科学 | 650篇 |
皮肤病学 | 62篇 |
神经病学 | 381篇 |
特种医学 | 102篇 |
外科学 | 590篇 |
综合类 | 15篇 |
一般理论 | 6篇 |
预防医学 | 335篇 |
眼科学 | 22篇 |
药学 | 371篇 |
中国医学 | 4篇 |
肿瘤学 | 198篇 |
出版年
2021年 | 35篇 |
2020年 | 35篇 |
2019年 | 40篇 |
2018年 | 83篇 |
2017年 | 72篇 |
2016年 | 80篇 |
2015年 | 75篇 |
2014年 | 78篇 |
2013年 | 160篇 |
2012年 | 163篇 |
2011年 | 123篇 |
2010年 | 103篇 |
2009年 | 92篇 |
2008年 | 161篇 |
2007年 | 144篇 |
2006年 | 142篇 |
2005年 | 157篇 |
2004年 | 106篇 |
2003年 | 146篇 |
2002年 | 139篇 |
2001年 | 107篇 |
2000年 | 129篇 |
1999年 | 120篇 |
1998年 | 58篇 |
1997年 | 61篇 |
1996年 | 48篇 |
1995年 | 39篇 |
1994年 | 37篇 |
1993年 | 53篇 |
1992年 | 144篇 |
1991年 | 130篇 |
1990年 | 124篇 |
1989年 | 114篇 |
1988年 | 86篇 |
1987年 | 92篇 |
1986年 | 90篇 |
1985年 | 73篇 |
1984年 | 74篇 |
1983年 | 55篇 |
1982年 | 35篇 |
1980年 | 30篇 |
1979年 | 51篇 |
1978年 | 42篇 |
1977年 | 38篇 |
1976年 | 34篇 |
1975年 | 30篇 |
1974年 | 38篇 |
1973年 | 43篇 |
1971年 | 32篇 |
1970年 | 30篇 |
排序方式: 共有4354条查询结果,搜索用时 11 毫秒
991.
992.
Aldo P. Maggioni Ulf Dahlstrm Gerasimos Filippatos Ovidiu Chioncel Marisa Crespo Leiro Jaroslaw Drozdz Friedrich Fruhwald Lars Gullestad Damien Logeart Gianna Fabbri Renato Urso Marco Metra John Parissis Hans Persson Piotr Ponikowski Mathias Rauchhaus Adriaan A. Voors Olav Wendelboe Nielsen Faiez Zannad Luigi Tavazzi 《European journal of heart failure》2013,15(7):808-817
993.
A. C. Shore H. M. Colhoun A. Natali C. Palombo G. Östling K. Aizawa C. Kennbäck F. Casanova M. Persson K. Gooding P. E. Gates F. Khan H. C. Looker F. Adams J. Belch S. Pinnoli E. Venturi C. Morizzo I. Goncalves C. Ladenvall J. Nilsson the SUMMIT consortium 《Journal of internal medicine》2015,278(3):291-302
994.
Dosage-dependent release of 45Ca was observed from prelabeled mouse calvarial bones after treatment with two thiazolidinediones, troglitazone and ciglitazone. Release of 45Ca by ciglitazone was decreased by the osteoclast inhibitors acetazolamide, calcitonin, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate, and IL-4, but not affected by the peroxisome proliferator-activated receptor gamma antagonist, GW 9662, the mitotic inhibitor, hydroxyurea, or indomethacin. Enhanced expression of receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA and protein and decreased osteoprotegerin (OPG) mRNA and protein were noted after ciglitazone treatment of calvariae. Ciglitazone and RANKL each caused increased mRNA expression of osteoclast markers: calcitonin receptor, tartrate-resistant acid phosphatase, cathepsin K, matrix metalloproteinase-9, integrin beta3, and nuclear factor of activated T cells 2. OPG inhibited mRNA expression of RANKL stimulated by ciglitazone, mRNA expression of osteoclast markers stimulated by ciglitazone and RANKL, and 45Ca release stimulated by troglitazone and ciglitazone. Increased expression of IL-1alpha mRNA by ciglitazone was not linked to resorption stimulated by the thiazolidinedione. Ciglitazone did not increase adipogenic gene expression but enhanced osteocalcin mRNA in calvariae. In addition to exhibiting sensitivity to OPG, data indicate that stimulation of osteoclast differentiation and activity by thiazolidinediones may occur by a nonperoxisome proliferator-activated receptor gamma-dependent pathway that does not require cell proliferation, prostaglandins, or IL-1alpha but is characterized by an increased RANKL to OPG ratio. 相似文献
995.
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease 总被引:4,自引:0,他引:4 下载免费PDF全文
Cortot A Colombel JF Rutgeerts P Lauritsen K Malchow H Hämling J Winter T Van Gossum A Persson T Pettersson E 《Gut》2001,48(2):186-190
BACKGROUND: Steroid dependent patients with Crohn's disease are at high risk of developing glucocorticosteroid induced side effects. AIMS: We evaluated the possibility of switching from systemic steroids to budesonide (Entocort) in prednisolone/prednisone dependent patients with inactive Crohn's disease affecting the ileum and/or ascending colon. PATIENTS: Steroid dependent patients with a Crohn's disease activity index =200 were included. METHODS: In a double blind multicentre trial, 120 patients were randomly assigned to receive budesonide 6 mg once daily or placebo. Prednisolone was tapered to zero during the first 4-10 weeks and budesonide or placebo was given concomitantly and for a further 12 weeks. Relapse was defined as an index >200 and an increase of 60 points from baseline or withdrawal due to disease deterioration. RESULTS: After one and 13 weeks without prednisolone, relapse rates were 17% and 32%, respectively, in the budesonide group, and 41% and 65% in the placebo group (95% confidence intervals for the difference in percentages -41%, -8% and -51%, -16%; p=0.004 and p<0.001, respectively). The number of glucocorticosteroid side effects was reduced by 50% by switching from prednisolone and was similar in the budesonide and placebo groups. Basal plasma cortisol increased in both groups. CONCLUSIONS: The majority of patients with steroid dependent ileocaecal Crohn's disease may be switched to budesonide controlled ileal release capsules 6 mg without relapse, resulting in a sharp decrease in glucocorticosteroid side effects similar to placebo, and with an increase in plasma cortisol levels. 相似文献
996.
Compartment syndrome after prolonged surgery with leg supports 总被引:3,自引:0,他引:3
D. Bergqvist M. Bohe G. Ekelund S. Hellsten H. Jiborn N. H. Persson R. Takolander 《International journal of colorectal disease》1990,5(1):1-5
Compartment syndrome has been reported in a few cases after prolonged surgery with patients in leg supports. A recent case in our hospital (57-year-old man undergoing cystourethrectomy because of cancer) made us interested in the problem. This case together with six from the literature are analysed. Moreover, the first 11 cases operated on with a pelvic pouch and ileoanal anastomosis at our department were reviewed. They had been in the leg support position for a median duration of 6.4 (5.8–8) h. In four of them leg pain and swelling developed within 12 h. Three showed regression within a few days, one after a week. In one patient with swelling compartment pressure was measured with a transducer tipped catheter. Intermittently the pressure was up to 50 mm Hg. There was an obvious decrease in pressure on knee bending. Also, in a patient without swelling large pressure variations were seen but not to critical levels. 相似文献
997.
998.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized,placebo‐controlled,double‐blind,crossover trial 下载免费PDF全文
Bernt Johan von Scholten MD Frederik Persson MD DMSc Signe Rosenlund MD Jesper Eugen‐Olsen PhD Tomasz Pielak BSc Jens Faber MD DMSc Tine W. Hansen MD PhD Peter Rossing MD DMSc 《Diabetes, obesity & metabolism》2017,19(6):901-905
We assessed the effects of liraglutide treatment on five cardiovascular risk biomarkers, reflecting different pathophysiology: tumour necrosis factor (TNF)‐α; soluble urokinase plasminogen activator receptor (suPAR); mid‐regional pro‐adrenomedullin (MR‐proADM); mid‐regional pro‐atrial natriuretic peptide (MR‐proANP); and copeptin, in people with type 2 diabetes with albuminuria. In a randomized, double‐blind, placebo‐controlled, crossover trial we enrolled people with type 2 diabetes and persistent albuminuria (urinary albumin‐to‐creatinine ratio [UACR] >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. Participants received liraglutide (1.8 mg/d) and matched placebo for 12 weeks, in random order. The primary endpoint was change in albuminuria; this was a prespecified sub‐study. A total of 32 participants were randomized, of whom 27 completed the study. TNF‐α level was 12% (95% confidence interval [CI] 3; 20) lower after liraglutide treatment compared with placebo (P = .012); MR‐proADM level was 4% (95% CI 0; 8) lower after liraglutide treatment compared with placebo (P = .038), and MR‐proANP level was 13% (95% CI 4; 21) lower after liraglutide treatment compared with placebo (P = .006). In the present study, we showed anti‐inflammatory effects of liraglutide treatment, reflected in reductions in levels of TNF‐α and MR‐proADM, while the reduction in MR‐proANP levels may represent a clinically relevant benefit with regard to heart failure. 相似文献
999.
Sren Persson Hans Linde Nielsen John Eugenio Coia Jrgen Engberg Bente Scharvik Olesen Anne Line Engsbro Andreas Munk Petersen Hanne Marie Holt Lars Lemming Ea Sofie Marmolin Turid Snekloth Sndergaard Leif Percival Andersen Mie Birgitte Frid Jensen Camilla Wiuff Gitte Srensen Sofie Holtsmark Nielsen Eva Mller Nielsen 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2022,27(49)
BackgroundSince 2008, Danish national surveillance of Clostridioides difficile has focused on binary toxin-positive strains in order to monitor epidemic types such as PCR ribotype (RT) 027 and 078. Additional surveillance is needed to provide a more unbiased representation of all strains from the clinical reservoir.AimSetting up a new sentinel surveillance scheme for an improved understanding of type distribution relative to time, geography and epidemiology, here presenting data from 2016 to 2019.MethodsFor 2─4 weeks in spring and autumn each year between 2016 and 2019, all 10 Danish Departments of Clinical Microbiology collected faecal samples containing toxigenic C. difficile. Isolates were typed at the national reference laboratory at Statens Serum Institut. The typing method in 2016–17 used tandem-repeat-sequence typing, while the typing method in 2018–19 was whole genome sequencing.ResultsDuring the study period, the sentinel surveillance scheme included ca 14–15% of all Danish cases of C. difficile infections. Binary toxin-negative strains accounted for 75% and 16 of the 20 most prevalent types. The most common sequence types (ST) were ST2/13 (RT014/020) (19.5%), ST1 (RT027) (10.8%), ST11 (RT078) (6.7%), ST8 (RT002) (6.6%) and ST6 (RT005/117) (5.1%). The data also highlighted geographical differences, mostly related to ST1 and temporal decline of ST1 (p = 0.0008) and the increase of ST103 (p = 0.002), ST17 (p = 0.004) and ST37 (p = 0.003), the latter three binary toxin-negative.ConclusionSentinel surveillance allowed nationwide monitoring of geographical differences and temporal changes in C. difficile infections in Denmark, including emerging types, regardless of binary toxin status. 相似文献
1000.